Further research is needed to elucidate the downstream signaling pathways involved in the anti-angiogenic function of AZGP1 for a comprehensive understanding of this important clinical biomarker of PCa aggressiveness. The gene discussed is AZGP1; the disease is posterior cortical atrophy.